Tresiba U200 delivers lower rates of hypoglycaemia

New data show that patients with type 2 diabetes receiving the U200 formulation of Tresiba experienced significantly lower rates of confirmed hypoglycaemia and significantly reduced mean fasting blood glucose compared to those receiving insulin glargine U100. European Pharmaceutical Review
Source: Society for Endocrinology - Category: Endocrinology Source Type: news